J Pain Symptom Manage. 2010 Nov;40(5):747-60. Epub 2010 Jul 1.
Long-term safety and tolerability of fentanyl buccal tablet for the treatment of
breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month
study.
Fine PG, Messina J, Xie F, Rathmell J.
Department of Anesthesiology, Pain Management Center, Suite 200, 615 Arapeen
Drive, University of Utah, Salt Lake City, UT 84109, USA.
[email protected]
CONTEXT: Breakthrough pain (BTP) is highly prevalent in patients with chronic
cancer and noncancer pain, commonly requiring treatment with short-acting or
rapid-onset opioids. This is the first report of an analysis of long-term safety
from combined clinical trials of a rapid-onset transmucosal formulation of
fentanyl, the fentanyl buccal tablet (FBT).
OBJECTIVES: This long-term (18-month), open-label study assessed the safety and
tolerability of FBT for the treatment of BTP in a large cohort (n=646) of
opioid-tolerant patients receiving around-the-clock (ATC) opioids for persistant
noncancer pain.
METHODS: This was a long-term, multicenter, open-label safety study that accepted
patients naïve to FBT (new patients) as well as rollover patients from one of two
previous short-term, randomized, placebo-controlled studies involving
opioid-tolerant adults with chronic noncancer pain. All patients gave written
informed consent, and the study was conducted according to Good Clinical Practice
and with Independent Ethics Committee or Institutional Review Board approval.
RESULTS: During maintenance treatment, 70 of 646 patients (11%) discontinued
because of adverse events (AEs), 69 of 646 (11%) because of withdrawn consent,
and 57 of 646 (9%) because of noncompliance. A total of 571 of 646 patients (88%)
had one or more AEs; most were mild to moderate in intensity and typical of AEs
associated with opioid use in a noncancer chronic pain population. Serious AEs
were seen in 118 of 646 patients (18%); most were considered by the investigators
to be unrelated or unlikely to be related to FBT. There were six deaths (three
myocardial infarction, two cardiac arrest, and one pneumonia) that were
considered by investigators to be unrelated or unlikely to be related to FBT.
There were two reports of accidental overdose contained within nine reports of
nonfatal overdose (FBT and/or ATC and/or other medications). Four patients had
AEs of abuse or drug dependence, two in association with FBT. Drug withdrawal
syndrome occurred in 23 patients after discontinuation of FBT alone or in
combination with other opioids. Secondary assessments showed that average pain
ratings, as assessed by the Brief Pain Inventory, remained relatively stable
throughout the study and that consistent improvements were noted in functional
measures.
CONCLUSION: FBT was generally safe and well tolerated, with self-reported
functional improvement observed in most of the opioid-tolerant patients with BTP
in association with chronic noncancer pain.